Health Care Modeling For Forecasting Quality And Cost Outcomes Also Addresses Clinical Trial Needs
Archimedes, Inc.
, a San Francisco-based healthcare modeling company, and the
Robert Wood Johnson Foundation
announced that the US Department of Health and Human Services (HHS) has contracted with Archimedes to provide HHS agencies with direct access to the
ARCHeS Innovator
. The Archimedes Model, developed initially with support from Kaiser Permanente, is an advanced mathematical modeling tool available to answer complex questions on health and health care. Under this contract, HHS will make a new web-based interface called the Archimedes Healthcare Simulator (ARCHeS) available to its agencies, including the Centers for Medicare and Medicaid Services, the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality, the National Heart, Lung & Blood Institute and the Food & Drug Administration. For clinical trials, the modeling tool will users to run clinically realistic virtual trials on any population and to help with comparative effectiveness research, and clinical trial design and portfolio management.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
